Get the Stockscreener App
6.195
0.08%
-0.005
After Hours:
6.19
-0.005
-0.08%
Aclarion Inc stock is traded at $6.195, with a volume of 304.37K.
It is down -0.08% in the last 24 hours and up +2.18% over the past month.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
See More
Previous Close:
$6.20
Open:
$6.3
24h Volume:
304.37K
Relative Volume:
2.04
Market Cap:
$4.16M
Revenue:
$49,300
Net Income/Loss:
$-6.27M
P/E Ratio:
-0.6815
EPS:
-9.09
Net Cash Flow:
$-5.38M
1W Performance:
+1.39%
1M Performance:
+2.18%
6M Performance:
-14.20%
1Y Performance:
+83.70%
1-Day Range:
$5.97
$6.40
1-Week Range:
$5.81
$6.40
52-Week Range:
$0.7425
$562.68
Aclarion Inc Stock (ACON) Company Profile
Name
Aclarion Inc
Sector
Industry
Phone
833 275 2266
Address
8181 ARISTA PLACE, BROOMFIELD
Compare ACON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
6.195 | 4.16M | 49,300 | -6.27M | -5.38M | -9.09 |
|
VEEV
Veeva Systems Inc
|
223.36 | 36.47B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
65.92 | 11.47B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
44.98 | 8.22B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
93.78 | 8.16B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
38.00 | 6.76B | 11.99B | 24.18M | 234.31M | 0.2956 |
Aclarion Inc Stock (ACON) Latest News
What margin trends mean for Aclarion Inc. stock2025 Risk Factors & High Conviction Buy Zone Picks - Улправда
Is Aclarion Inc. stock a smart buy before Fed meeting2025 Fundamental Recap & Reliable Breakout Forecasts - Улправда
Trading Action: Why Aclarion Inc. stock appeals to dividend seekersMarket Risk Report & Daily Growth Stock Investment Tips - Улправда
Is Aclarion Inc. stock cheap at current valuationPortfolio Value Summary & Growth-Oriented Investment Plans - Улправда
Retail Trends: Why Aclarion Inc. stock is seen as undervaluedShare Buyback & Community Consensus Picks - Улправда
Can Aclarion Inc. stock hit record highs again2025 Support & Resistance & Weekly Top Stock Performers List - Улправда
How Aclarion Inc. Equity Warrant stock benefits from global expansionGap Up & Long-Term Safe Investment Plans - Улправда
Will Aclarion Inc. Equity Warrant stock gain from strong economyEarnings Recap Summary & Community Trade Idea Sharing Platform - Улправда
Fund Flows: What margin trends mean for Aclarion Inc. stockMarket Performance Summary & Weekly Consistent Profit Watchlists - Улправда
Why Aclarion Inc. stock is seen as undervaluedPortfolio Risk Summary & High Conviction Buy Zone Alerts - Улправда
Is Aclarion Inc. Equity Warrant stock a safe haven asset2025 Investor Takeaways & Target Return Focused Stock Picks - DonanımHaber
Sell Signal: What margin trends mean for Aclarion Inc. stock2025 Trading Volume Trends & Weekly Hot Stock Watchlists - Улправда
Why Aclarion Inc. stock appeals to dividend seekersMarket Rally & Expert Approved Momentum Trade Ideas - ulpravda.ru
Growth Value: What makes Aclarion Inc. (IT20) stock appealing to growth investorsWeekly Trade Review & Technical Analysis for Trade Confirmation - Улправда
Aclarion Earnings Notes - Trefis
Nasdaq Moves: Will ATLCP stock continue upward momentumWeekly Stock Summary & Daily Risk Controlled Trade Plans - moha.gov.vn
Ramsay Health Care (OTCMKTS:RMYHY) vs. Aclarion (NASDAQ:ACON) Financial Review - Defense World
What drives Aclarion Inc stock priceReal Estate Investment Trusts & These 3 Stocks Could Change Your Portfolio - earlytimes.in
Aclarion shares move higher after Nociscan highlighted in spine surgery journal - MSN
Aclarion announces publication of Nociscan article in pain issue of IJSS - MSN
Aclarion (ACON) Price Target Increased by 15.00% to 23.46 - Nasdaq
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) - Orthopedics This Week
Can Aclarion Inc. Equity Warrant stock maintain growth trajectory2025 Retail Activity & Free Real-Time Market Sentiment Alerts - Newser
Aclarion Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Will Aclarion Inc. stock deliver better than expected guidance2025 Performance Recap & AI Forecast Swing Trade Picks - Newser
Aclarion’s Nociscan featured in special pain issue of spine journal By Investing.com - Investing.com Nigeria
Is Aclarion Inc. (IT20) stock vulnerable to rate hikes2025 Bull vs Bear & Technical Pattern Based Buy Signals - Newser
How Aclarion Inc. (IT20) stock gains from tech spendingMarket Performance Recap & Weekly Stock Performance Updates - Newser
Why Aclarion Inc. (IT20) stock stays resilientJuly 2025 Decliners & Target Return Focused Picks - Newser
How sustainable is Aclarion Inc. Equity Warrant stock dividend payout2025 Market Trends & Detailed Earnings Play Alerts - Newser
Aclarion, Inc. Stock (ACON) Opinions on Nociscan Technology Publication - Quiver Quantitative
Aclarion stock rises after feature in special pain issue of spine journal By Investing.com - Investing.com South Africa
Aclarion stock rises after feature in special pain issue of spine journal - Investing.com Canada
Aclarion’s Nociscan featured in special pain issue of spine journal - Investing.com
ACON FinancialsIncome Statement - Quiver Quantitative
Aclarion's Nociscan Featured in International Journal of Spine Surgery's Special Pain Issue, Highlighting Advances in Chronic Low Back Pain Diagnosis - Quiver Quantitative
Aclarion (Nasdaq: ACON) Nociscan case study guides targeted spine surgery - Stock Titan
Can Aclarion Inc. (IT20) stock sustain double digit ROEJuly 2025 Rallies & AI Powered Buy and Sell Recommendations - Newser
Is Aclarion Inc. (IT20) stock suitable for passive index fundsJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - Newser
Will Aclarion Inc. (IT20) stock sustain uptrend momentumQuarterly Trade Report & Smart Swing Trading Techniques - Newser
Will Aclarion Inc. stock remain a Wall Street favoriteIPO Watch & Target Return Focused Stock Picks - Newser
Aug Intraday: Will QRAFT AI Enhanced U.S. Large Cap stock return to pre crash levelsJuly 2025 PostEarnings & Low Risk High Win Rate Stock Picks - BỘ NỘI VỤ
Will Aclarion Inc. Equity Warrant stock reach Wall Street targets2025 Momentum Check & Real-Time Chart Pattern Alerts - Newser
How Aclarion Inc. stock performs in high volatility marketsTrade Exit Report & Advanced Swing Trade Entry Plans - Newser
Will Aclarion Inc. (IT20) stock outperform energy sector in 20252025 Volatility Report & AI Powered Market Trend Analysis - Newser
Aclarion, Inc. Appoints Jason Brosniak as Commercial Director for the Eastern U.S - marketscreener.com
Aclarion, Inc. (ACON) 15.7% in Intraday Trading: Appointment of Commercial Director Drives Interest - Stocks Telegraph
Aclarion appoints Jason Brosniak as commercial director, Eastern U.S. - TipRanks
Press Release: Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S. - 富途牛牛
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S. - The Globe and Mail
Is Aclarion's Debt-Free Position The Backbone Of Its Next Phase Of Expansion? - RTTNews
Aclarion Inc Stock (ACON) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):